Literature DB >> 7033057

Immunohistochemical analysis of HLA (A, B, C) antigens in liver disease using a monoclonal antibody.

C Barbatis, J Woods, J A Morton, K A Fleming, A McMichael, J O McGee.   

Abstract

The distribution of HLA class I antigens was studied in 42 liver biopsies and eight necropsies by an immunoperoxidase technique employing a monoclonal antibody which reacts with the heavy chains of class I (A, B, C) HLA antigens. In normal liver HLA class I antigens could not be detected on hepatocyte cell membranes or cytoplasm; these antigens were present on the cell membrane of bile duct epithelium, on sinusoidal lining cells, fibroblasts, and blood vessel endothelium. However, in all patients with acute alcoholic hepatitis, most cases of primary biliary cirrhosis and some cases of chronic active hepatitis HLA class I antigens were detectable focally or diffusely on the cell membrane of hepatocytes; in two cases of acute viral hepatitis (non-A, non-B) HLA class I antigens were present in granular form in the cytoplasm of all hepatocytes. These findings may be relevant to the prolonged survival of liver allografts in man and other species and in the pathogenesis of some liver diseases.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7033057      PMCID: PMC1419485          DOI: 10.1136/gut.22.12.985

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  The major histocompatibility complex of the mouse.

Authors:  J Klein
Journal:  Science       Date:  1979-02-09       Impact factor: 47.728

2.  The distribution of HLA on human lymphoid, bone marrow and peripheral blood cells.

Authors:  G Brown; P Biberfeld; B Christensson; D Y Mason
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  A study of HL-A antigens in human organs.

Authors:  M Berah; J Hors; J Dausset
Journal:  Transplantation       Date:  1970-03       Impact factor: 4.939

Review 5.  HLA--a central immunological agency of man.

Authors:  D B Amos; D D Kostyu
Journal:  Adv Hum Genet       Date:  1980

6.  Distribution and quantitation of HLA-ABC and DR (Ia) antigens on human kidney and other tissues.

Authors:  K A Williams; D N Hart; J W Fabre; P J Morris
Journal:  Transplantation       Date:  1980-04       Impact factor: 4.939

Review 7.  HLA restriction of human cytotoxic T cells.

Authors:  A J McMichael
Journal:  Springer Semin Immunopathol       Date:  1980-05

8.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1979-05-15       Impact factor: 7.396

9.  Demonstration of HLA restricted killer cells in patients with acute measles.

Authors:  H W Kreth; V ter Meulen; G Eckert
Journal:  Med Microbiol Immunol       Date:  1979-01-24       Impact factor: 3.402

10.  Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer.

Authors:  K A Fleming; A McMichael; J A Morton; J Woods; J O McGee
Journal:  J Clin Pathol       Date:  1981-07       Impact factor: 3.411

View more
  21 in total

1.  Distribution of the MHC antigens after liver transplantation: relationship with biochemical and histological parameters.

Authors:  P Rouger; J Gugenheim; P Gane; M Capron-Landereau; F Michel; M Reynes; J Bismuth
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Soluble HLA class I antigens in sera of patients with chronic hepatitis.

Authors:  K Sakaguchi; N Koide; T Takenami; H Matsushima; H Takabatake; S Ferrone; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1992-04

3.  Hepatocellular expression of a novel glycoprotein with sialylated difucosyl Lex activity in the active inflammatory lesions of chronic liver disease.

Authors:  Y Okada; T Shimoe; M Muguruma; R Usumoto; T Tsuji; K Jinno; S Moriwaki; S Shin; S Hakomori
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

4.  PLP fixation for combined routine histology and immunocytochemistry of liver biopsies.

Authors:  F Brenes; S Harris; M O Paz; L M Petrovic; P J Scheuer
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

5.  Immunohistochemical study of HLA class 1 antigens on the hepatocytes of patients with chronic hepatitis B.

Authors:  K Manabe; G Yamada; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1986-08

6.  Expression of HLA class I antigens on hepatocytes in liver disease.

Authors:  T Fukusato; M A Gerber; S N Thung; S Ferrone; F Schaffner
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

7.  Disorganisation of intermediate filament structure in alcoholic and other liver diseases.

Authors:  C Barbatis; J Morton; J C Woods; J Burns; J Bradley; J O McGee
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

8.  HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease.

Authors:  G Ballardini; F B Bianchi; R Mirakian; M Fallani; E Pisi; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

9.  The biliary epithelium presents antigens to and activates natural killer T cells.

Authors:  Elisabeth Schrumpf; Corey Tan; Tom H Karlsen; Jon Sponheim; Niklas K Björkström; Olav Sundnes; Kristian Alfsnes; Arthur Kaser; Douglas M Jefferson; Yoshiyuki Ueno; Tor J Eide; Guttorm Haraldsen; Sebastian Zeissig; Mark A Exley; Richard S Blumberg; Espen Melum
Journal:  Hepatology       Date:  2015-05-20       Impact factor: 17.425

10.  Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines.

Authors:  R C Ayres; J M Neuberger; J Shaw; R Joplin; D H Adams
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.